Verastem, Inc. (VSTM) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.77
+5% vs avg
5yr avg: 4.55
30Y Low0.6·High13.9
ROE
↓
-1480.2%
↑-170% vs avg
5yr avg: -548.8%
30Y Low-227%·High-40%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VSTM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Verastem, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $273M | $535M | $185M | $180M | $77M | $358M | $327M | $100M | $233M | $118M | $41M |
| Enterprise Value | $145M | $407M | $138M | $143M | $30M | $339M | $281M | $164M | $224M | $51M | $9M |
| P/E Ratio → | -1.30 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.83 | 17.31 | 18.46 | — | 29.84 | 174.15 | 3.69 | 5.72 | 8.72 | — | — |
| P/B Ratio | 4.77 | 9.35 | — | 3.13 | 1.63 | 4.08 | 2.83 | 13.93 | 1.87 | 2.04 | 0.57 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VSTM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.16 | 13.81 | — | 11.40 | 165.35 | 3.18 | 9.39 | 8.37 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
VSTM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Verastem, Inc. earns an operating margin of -550.3%. Operating margins have expanded from -1149.6% to -550.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -1480.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.9% | 82.9% | 100.0% | — | 100.0% | 100.0% | 61.9% | 83.9% | 97.8% | — | — |
| Operating Margin | -550.3% | -550.3% | -1149.6% | — | -2809.6% | -2991.2% | -55.8% | -758.1% | -354.8% | — | — |
| Net Profit Margin | -677.6% | -677.6% | -1306.4% | — | -2843.3% | -3468.1% | -76.5% | -854.8% | -271.1% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1480.2% | -1480.2% | -917.4% | -166.8% | -109.4% | -70.2% | -110.6% | -227.0% | -79.6% | -104.3% | -41.7% |
| ROA | -120.4% | -120.4% | -104.0% | -71.4% | -72.5% | -54.1% | -45.2% | -70.7% | -39.5% | -78.2% | -37.0% |
| ROIC | — | — | — | -672.3% | -158.5% | -66.0% | -52.4% | -106.7% | -135.1% | -335.8% | -47.2% |
| ROCE | -139.0% | -139.0% | -118.6% | -93.6% | -89.2% | -54.0% | -39.1% | -74.5% | -60.6% | -93.3% | -42.1% |
VSTM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $205M exceeds total debt of $77M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.34 | 1.34 | — | 0.72 | 0.57 | 0.04 | 0.20 | 14.99 | 0.97 | 0.26 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.24 | — | -0.63 | -1.01 | -0.21 | -0.39 | 8.92 | -0.08 | -1.17 | -0.45 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -149.50 | -149.50 | -27.60 | -20.11 | -33.54 | -6.14 | -3.28 | -6.24 | -11.47 | -120.29 | — |
Net cash position: cash ($205M) exceeds total debt ($77M)
VSTM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Verastem, Inc.'s current ratio of 3.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.45x to 3.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 3.07 | 5.45 | 4.29 | 5.69 | 8.48 | 2.84 | 6.83 | 5.13 | 7.40 |
| Quick Ratio | 3.07 | 3.07 | 3.07 | 5.45 | 4.29 | 5.69 | 8.48 | 2.74 | 6.82 | 5.13 | 7.40 |
| Cash Ratio | 2.84 | 2.84 | 2.87 | 5.20 | 4.06 | 5.39 | 8.26 | 2.53 | 6.73 | 5.06 | 7.36 |
| Asset Turnover | — | 0.13 | 0.10 | — | 0.03 | 0.02 | 0.57 | 0.12 | 0.10 | — | — |
| Inventory Turnover | 2.89 | 2.89 | — | — | — | — | — | 0.91 | 1.80 | — | — |
| Days Sales Outstanding | — | 104.05 | 7.30 | — | 4.36 | 91.74 | 0.99 | 52.78 | 4.18 | — | — |
VSTM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Verastem, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $69M | $36M | $22M | $16M | $15M | $13M | $6M | $6M | $3M | $3M |
Peer Comparison
Compare VSTM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VSTMYou | $273M | -1.3 | — | — | 82.9% | -550.3% | -1480.2% | — | — |
 KPTI | $77M | -0.5 | — | — | 95.9% | -62.1% | — | — | — |
 MGNX | $255M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 TGTX | $7B | 17.3 | 61.0 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 PRME | $509M | -2.1 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 AGEN | $141M | -997.1 | — | — | 29.6% | -18.0% | — | — | — |
 IDYA | $3B | -22.5 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 NVCR | $2B | -14.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 PTCT | $6B | 9.6 | 6.4 | 8.8 | 95.9% | 49.5% | — | — | 0.5 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
What if you invested $1,000 in VSTM 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in VSTM be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs VSTM Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationVSTM vs KPTI — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Karyopharm Therapeutics Inc..
Compare NowVSTM — Frequently Asked Questions
Quick answers to the most common questions about buying VSTM stock.
What is Verastem, Inc.'s P/E ratio?
Verastem, Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
What is Verastem, Inc.'s ROE?
Verastem, Inc.'s return on equity (ROE) is -1480.2%. The historical average is -95.3%.
Is VSTM stock overvalued?
Based on historical data, Verastem, Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Verastem, Inc.'s profit margins?
Verastem, Inc. has 82.9% gross margin and -550.3% operating margin.